Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow.

Journal: European journal of cancer (Oxford, England : 1990)
Published Date:

Abstract

Patient care workflows are highly multimodal and intertwined: the intersection of data outputs provided from different disciplines and in different formats remains one of the main challenges of modern oncology. Artificial Intelligence (AI) has the potential to revolutionize the current clinical practice of oncology owing to advancements in digitalization, database expansion, computational technologies, and algorithmic innovations that facilitate discernment of complex relationships in multimodal data. Within oncology, radiation therapy (RT) represents an increasingly complex working procedure, involving many labor-intensive and operator-dependent tasks. In this context, AI has gained momentum as a powerful tool to standardize treatment performance and reduce inter-observer variability in a time-efficient manner. This review explores the hurdles associated with the development, implementation, and maintenance of AI platforms and highlights current measures in place to address them. In examining AI's role in oncology workflows, we underscore that a thorough and critical consideration of these challenges is the only way to ensure equitable and unbiased care delivery, ultimately serving patients' survival and quality of life.

Authors

  • Marisa Cobanaj
    Department of Electronics Informatics and Bioengineering, Polytechnic University of Milan, Milan, Italy.
  • Chiara Corti
    Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy. Electronic address: chiara.corti@ieo.it.
  • Edward C Dee
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lucas McCullum
    Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
  • Laura Boldrini
    Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy.
  • Ilana Schlam
    Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Sara M Tolaney
    See the Notes section for the full list of authors' affiliations.
  • Leo A Celi
    Beth Israel Deaconess Medical Center, Pulmonary Division and Harvard Medical School, Boston, MA 02215, USA.
  • Giuseppe Curigliano
    Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy.
  • Carmen Criscitiello
    Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan 20141, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan 20122, Italy.